74 related articles for article (PubMed ID: 1648808)
1. Pathogenesis of CMV-associated diseases in 1990.
Zaia JA
Transplant Proc; 1991 Jun; 23(3 Suppl 3):1-4. PubMed ID: 1648808
[No Abstract] [Full Text] [Related]
2. Metabolic and cellular effects of human cytomegalovirus infection.
Albrecht T; Fons MP; Boldogh I; AbuBakar S; Deng CZ; Millinoff D
Transplant Proc; 1991 Jun; 23(3 Suppl 3):48-54, discussion 54-5. PubMed ID: 1648835
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors.
Kondo K; Mocarski ES
Scand J Infect Dis Suppl; 1995; 99():63-7. PubMed ID: 8668945
[TBL] [Abstract][Full Text] [Related]
4. Relevance of immune responses to pathogenesis of cytomegalovirus-associated diseases.
Gehrz RC; Liu YN; Eckhardt J; Klaus A
Transplant Proc; 1991 Jun; 23(3 Suppl 3):75-84. PubMed ID: 1648841
[No Abstract] [Full Text] [Related]
5. Murine models of cytomegalovirus-associated pneumonitis.
Shanley JD
Transplant Proc; 1991 Jun; 23(3 Suppl 3):12-6, discussion 16. PubMed ID: 1648814
[TBL] [Abstract][Full Text] [Related]
6. Importance of CMV in the transplant population.
Rubin RH
Transpl Infect Dis; 1999; 1 Suppl 1():3-7. PubMed ID: 11565584
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and therapy of cytomegalovirus (CMV)-associated lung disease following anti-CD3 monoclonal antibody treatment in mice with persistent murine CMV in the salivary glands.
Tanaka K; Koga Y; Kimura G; Nomoto K
Transplant Proc; 1995 Feb; 27(1):499-500. PubMed ID: 7879076
[No Abstract] [Full Text] [Related]
8. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.
Gómez E; Laurés A; Baltar JM; Melón S; Díez B; de Oña M
Transplant Proc; 2005 Nov; 37(9):3760-3. PubMed ID: 16386530
[TBL] [Abstract][Full Text] [Related]
10. Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents.
Jayarama V; Marcello J; Ohagen A; Gibaja V; Lunderville D; Horrigan J; Chapman J; Lazo A
Transfusion; 2006 Sep; 46(9):1580-8. PubMed ID: 16965587
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-transmitted cytomegalovirus: lessons from a murine model.
Roback JD; Su L; Zimring JC; Hillyer CD
Transfus Med Rev; 2007 Jan; 21(1):26-36. PubMed ID: 17174218
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation.
Kijpittayarit S; Eid AJ; Brown RA; Paya CV; Razonable RR
Clin Infect Dis; 2007 May; 44(10):1315-20. PubMed ID: 17443468
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow dysfunction in irradiated, cytomegalovirus-infected mice.
Reddehase MJ
Transplant Proc; 1991 Jun; 23(3 Suppl 3):10-1, discussion 11. PubMed ID: 1648809
[No Abstract] [Full Text] [Related]
15. Pathogenicity: animal models.
Bruggeman CA; Li F; Stals FS
Scand J Infect Dis Suppl; 1995; 99():43-50. PubMed ID: 8668942
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.
Steininger C
Clin Microbiol Infect; 2007 Oct; 13(10):953-63. PubMed ID: 17803749
[TBL] [Abstract][Full Text] [Related]
17. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
O'Sullivan CE; Drew WL; McMullen DJ; Miner R; Lee JY; Kaslow RA; Lazar JG; Saag MS
J Infect Dis; 1999 Sep; 180(3):847-9. PubMed ID: 10438377
[TBL] [Abstract][Full Text] [Related]
18. Cell-activation responses to cytomegalovirus infection relationship to the phasing of CMV replication and to the induction of cellular damage.
Albrecht T; Boldogh I; Fons M; Lee CH; AbuBakar S; Russell JM; Au WW
Subcell Biochem; 1989; 15():157-202. PubMed ID: 2552622
[No Abstract] [Full Text] [Related]
19. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection.
Aulitzky WE; Hengster P; Tilg H; Schulz T; Dierich M; Huber C
Wien Klin Wochenschr; 1988 Jan; 100(2):33-43. PubMed ID: 2831672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
